BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 24, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes

Wk chg 8/21 cls
Company Bank Analyst Coverage Opinion
Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) Dundee David Martin Downgrade Neutral (from buy) -66% C$1.07
Martin also lowered his target to C$1 from C$3.50 after cetrorelix missed the primary endpoint in a Phase III trial to treat benign prostatic hyperplasia (BPH) (see "Hoping Phase II was Real," A12).
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Price target Market outperform -2% $42.23
Raymond lowered his target to $66 from $70. He noted his near-term revenue estimates for Feraheme ferumoxytol "may have...

Read the full 621 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >